New Share Alert | Okada Pharma Files for Hong Kong Listing

Stock News

01/27

It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors. According to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline. The company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151443681"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151443681\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151443681?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151443681","market":"sg","top_or_hot":-1,"title":"New Share Alert | Okada Pharma Files for Hong Kong Listing","media":"Stock News","content":"<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Share Alert | Okada Pharma Files for Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Share Alert | Okada Pharma Files for Hong Kong Listing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-27 08:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4020","symbol_name":"通信設備","start_time":0,"source_url":"","article_id":"1151443681","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151443681","pubTimestamp":1769472858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK4020":"通信设备","AUDC":"奥科","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"新股快讯|冈田制药申请香港上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1,"AUDC":1},"content_text":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}